If you have been researching medications for weight loss, you have probably encountered two names repeatedly: semaglutide and tirzepatide.

Patients frequently ask me, “Which one is better?” or “What is actually different about them?”

Both medications can be remarkably effective tools for treating obesity and improving metabolic health. But they are not the same medication, and there are some important differences in how they work, how much weight people tend to lose, and the clinical evidence available for each.

At Menopause Solutions in Mount Pleasant, South Carolina, we frequently see women who are doing all the “right” things—watching what they eat, exercising and trying to maintain healthy habits—but find that weight becomes increasingly difficult to manage during perimenopause and menopause.

Understanding these medications starts with understanding that obesity is far more complicated than simply “eat less and exercise more.”

First, What Are Semaglutide and Tirzepatide?

Semaglutide and tirzepatide belong to a newer generation of medications that influence the body's natural appetite and metabolic signaling pathways.

Semaglutide

Semaglutide is a GLP-1 receptor agonist.

GLP-1 stands for glucagon-like peptide-1, a hormone naturally released by the gastrointestinal tract after eating.

GLP-1 helps:

• Reduce hunger

• Increase feelings of fullness or satiety

• Slow gastric emptying

• Stimulate insulin release when glucose is elevated

• Reduce inappropriate glucagon secretion

• Improve blood sugar regulation

Semaglutide essentially amplifies this natural signaling system.

Semaglutide is marketed under several brand names, including Ozempic for type 2 diabetes and Wegovy for chronic weight management.

I discussed this mechanism in more detail in our article Semaglutide and Weight Loss. Read “Semaglutide and Weight Loss”

You may also want to read Emerging Frontiers with Semaglutide, where we discuss some of the health effects of semaglutide beyond simply seeing a smaller number on the scale. Read “Emerging Frontiers with Semaglutide”

Tirzepatide

Tirzepatide works somewhat differently.

It activates two hormone receptors instead of one:

GLP-1 + GIP

GIP stands for glucose-dependent insulinotropic polypeptide.

For this reason, tirzepatide is sometimes called a dual incretin receptor agonist.

Like semaglutide, tirzepatide can reduce hunger, increase satiety and improve glucose metabolism. But activating both the GIP and GLP-1 pathways appears to produce additional metabolic effects that may explain why tirzepatide has produced greater average weight loss in several clinical trials.

Tirzepatide is marketed as Mounjaro for type 2 diabetes and Zepbound for chronic weight management.

Semaglutide vs. Tirzepatide at a Glance

The biggest scientific question has therefore been:

Does activating both GIP and GLP-1 actually produce more weight loss than activating GLP-1 alone?

We now have a very good study addressing exactly that question.

What Did the Head-to-Head Study Find?

In 2025, the New England Journal of Medicine published SURMOUNT-5, one of the most important studies comparing these two medications because participants were randomized directly to tirzepatide or semaglutide rather than comparing results from completely separate clinical trials.

The study included adults with obesity but without diabetes and followed them for 72 weeks.

Participants received the maximum tolerated dose of either:

• Tirzepatide 10 or 15 mg weekly, or

• Semaglutide 1.7 or 2.4 mg weekly

The results were significant.

Average weight loss at 72 weeks:

Tirzepatide: 20.2%

Semaglutide: 13.7%

That translated into an average weight loss of approximately:

50 pounds with tirzepatide

versus

33 pounds with semaglutide.

Tirzepatide also produced a greater reduction in waist circumference. (New England Journal of Medicine)

Even more striking was the percentage of patients achieving larger degrees of weight loss.

Approximately:

• 81.6% of patients taking tirzepatide lost at least 10% of their body weight compared with 60.5% taking semaglutide.

• 64.6% lost at least 15% with tirzepatide compared with 40.1% with semaglutide.

• 48.4% lost at least 20% with tirzepatide compared with 27.3% with semaglutide.

• 31.6% lost at least 25% with tirzepatide compared with 16.1% with semaglutide. (OUP Academic)

So, at the doses studied in SURMOUNT-5, tirzepatide produced significantly greater average weight loss than semaglutide.

But There Is an Important 2026 Update

This is where interpreting medical studies carefully becomes important.

SURMOUNT-5 compared tirzepatide with semaglutide doses of 1.7 or 2.4 mg weekly.

Since that study was completed, a higher dose of injectable Wegovy—semaglutide 7.2 mg weekly—has been studied and FDA approved.

In the STEP UP trial, published in The Lancet Diabetes & Endocrinology, adults with obesity without diabetes receiving semaglutide 7.2 mg lost an average of approximately 18.7% of their starting weight using the treatment-policy analysis, compared with 15.6% with semaglutide 2.4 mg and 3.9% with placebo. (PubMed)

The FDA approved Wegovy 7.2 mg in March 2026 for certain adults with obesity or overweight with a weight-related condition. (U.S. Food and Drug Administration)

This does not mean we can conclude that 7.2 mg semaglutide is equivalent to tirzepatide.

Why?

Because semaglutide 7.2 mg and tirzepatide have not yet been compared directly in the same randomized head-to-head trial.

Comparing percentages from two completely different studies is not scientifically the same as directly comparing two medications in the same trial.

That distinction is important.

What Did the Original Semaglutide Studies Show?

Semaglutide dramatically changed the medical treatment of obesity when the STEP trials were published.

In the landmark STEP 1 trial, published in the New England Journal of Medicine in 2021, 1,961 adults with overweight or obesity without diabetes were randomized to semaglutide 2.4 mg or placebo along with lifestyle intervention.

Participants receiving semaglutide experienced substantial weight loss over 68 weeks, establishing GLP-1 therapy as one of the most effective nonsurgical approaches to obesity available at the time. (New England Journal of Medicine)

This represented a major advance over previous weight-loss medications.

What Did the Original Tirzepatide Study Show?

The landmark SURMOUNT-1 trial, published in the New England Journal of Medicine in 2022, studied 2,539 adults with obesity or overweight and a weight-related complication who did not have diabetes.

After 72 weeks, average weight loss was approximately:

• 15.0% with tirzepatide 5 mg

• 19.5% with tirzepatide 10 mg

• 20.9% with tirzepatide 15 mg

• 3.1% with placebo

More than half of participants receiving the 15 mg dose lost at least 20% of their body weight. (New England Journal of Medicine)

These results moved medical obesity treatment into territory that previously had been difficult to achieve without bariatric surgery.

What About Patients With Type 2 Diabetes?

The two medications were actually compared even before SURMOUNT-5.

In the SURPASS-2 trial, published in the New England Journal of Medicine in 2021, researchers studied 1,879 patients with type 2 diabetes receiving tirzepatide or semaglutide.

Tirzepatide produced greater reductions in both hemoglobin A1C and body weight than semaglutide 1 mg at the doses studied. (New England Journal of Medicine)

For women navigating both diabetes and menopause, we have additional information in Diabetes and Menopause: Strategies for Blood Sugar Control with Ozempic. Read our diabetes and menopause article

What About Heart Health?

This is another area where the answer is more nuanced than simply asking which medication causes the most weight loss.

Semaglutide has particularly strong cardiovascular outcome data.

The landmark SELECT trial enrolled adults with overweight or obesity who already had cardiovascular disease but did not have diabetes.

Semaglutide reduced the risk of cardiovascular death, nonfatal heart attack or nonfatal stroke compared with placebo. The results led the FDA to approve Wegovy to reduce the risk of major cardiovascular events in qualifying adults with cardiovascular disease and overweight or obesity. (New England Journal of Medicine)

This matters because our goal when treating obesity is not simply weight loss.

We are treating health risk.

Tirzepatide Has Another Interesting FDA-Approved Indication

In December 2024, the FDA approved Zepbound for adults with obesity and moderate-to-severe obstructive sleep apnea.

Clinical studies demonstrated significant improvements in sleep apnea severity along with substantial weight reduction. (U.S. Food and Drug Administration)

This can be particularly relevant during menopause because sleep disturbance, weight gain and sleep apnea frequently overlap.

Are the Side Effects Different?

The side-effect profiles of semaglutide and tirzepatide are fairly similar because both affect the GLP-1 pathway.

The most common side effects involve the gastrointestinal system and can include:

• Nausea

• Constipation

• Diarrhea

• Vomiting

• Abdominal discomfort

• Reflux

• Reduced appetite

These symptoms are generally most noticeable when treatment begins or when the dose is increased.

This is one reason I strongly prefer gradual dose escalation rather than racing to the highest possible dose.

The goal is not to take the most medication.

The goal is to use the lowest effective dose that achieves a healthy, sustainable response with acceptable side effects.

Is Tirzepatide Always Better Because It Causes More Weight Loss?

Not necessarily.

More weight loss is not automatically better for every patient.

A woman who needs to lose 15 pounds has a very different treatment goal from someone who needs to lose 75 pounds.

Medication selection may depend on:

• Starting BMI

• Amount of weight a patient needs or wants to lose

• Prediabetes or diabetes

• Cardiovascular disease

• Sleep apnea

• Gastrointestinal sensitivity

• Previous experience with GLP-1 medications

• Medication availability

• Insurance coverage and cost

• Ability to maintain adequate protein intake

• Muscle mass and body composition

• Individual response to treatment

And that last point is important.

Average weight loss in a clinical trial does not tell me exactly how an individual patient will respond.

Some patients respond extraordinarily well to semaglutide. Others respond much better to tirzepatide. Some tolerate one medication significantly better than the other.

Medicine still needs to be individualized.

What About Muscle Loss?

This is particularly important for women in perimenopause and menopause.

Any substantial weight loss—whether caused by dieting, bariatric surgery or medication—can include some loss of lean body mass.

Women are already vulnerable to age-related loss of skeletal muscle, known as sarcopenia, as they move through midlife.

That means GLP-1 treatment should not simply consist of:

Take medication. Eat less. Lose weight.

A responsible weight-management program should also emphasize:

• Adequate protein intake

• Resistance or strength training

• Regular physical activity

• Avoiding unnecessarily rapid weight loss

• Monitoring body composition when appropriate

The objective is not merely becoming lighter.

It is becoming metabolically healthier while preserving muscle and strength.

For more information about weight changes during menopause, see our article Weight Management in Menopause: How Ozempic Can Support Your Goals. Read about weight management during menopause

Do You Have to Stay on Semaglutide or Tirzepatide Forever?

This is one of the questions patients ask me most often.

Obesity behaves much more like other chronic metabolic conditions than a temporary problem that can simply be “cured” with a few months of medication.

When these medications are discontinued, appetite-regulating signals can change again, and weight regain is common.

That does not necessarily mean every patient must remain on exactly the same dose indefinitely.

Long-term treatment can involve individualized maintenance strategies, and ongoing research is helping us understand the best way to approach maintenance.

But patients should begin these medications understanding that weight management is generally a long-term process rather than a short-term diet.

Semaglutide vs. Tirzepatide: The Bottom Line

So what is the difference between semaglutide and tirzepatide?

The simplest explanation is:

Semaglutide activates the GLP-1 receptor.

Tirzepatide activates both the GIP and GLP-1 receptors.

Both can produce significant weight loss and meaningful improvements in metabolic health.

In the 2025 SURMOUNT-5 head-to-head study, tirzepatide produced greater average weight loss than semaglutide 1.7–2.4 mg: approximately 20.2% compared with 13.7% at 72 weeks. (New England Journal of Medicine)

However, the story has continued to evolve. Higher-dose semaglutide 7.2 mg subsequently produced greater weight loss than the 2.4 mg dose in the STEP UP trial and was FDA approved in 2026. We therefore should not assume that results from SURMOUNT-5 answer every future semaglutide-versus-tirzepatide question. (PubMed)

The better question is not simply:

“Which drug causes the most weight loss?”

It is:

“Which medication is most appropriate for this particular patient, her health risks, her goals and her ability to maintain muscle and metabolic health?”

That is where personalized medical care matters.

At Menopause Solutions in Mount Pleasant, SC, we work with women throughout Charleston, the Lowcountry and the Southeast to address weight gain and metabolic changes associated with perimenopause and menopause. When weight-loss medication is appropriate, we consider the entire patient—not simply the number on the scale.

Because successful weight management during menopause should be about much more than losing pounds.

It should be about improving health, strength, metabolic function and quality of life for the years ahead.

Frequently Asked Questions About Semaglutide vs. Tirzepatide

Is tirzepatide stronger than semaglutide?

At the doses compared directly in the SURMOUNT-5 trial, tirzepatide produced greater average weight loss than semaglutide 1.7–2.4 mg. However, semaglutide is now also available at a higher 7.2 mg dose, which was not studied in SURMOUNT-5.

Which causes more weight loss, semaglutide or tirzepatide?

In SURMOUNT-5, average weight loss at 72 weeks was approximately 20.2% with tirzepatide compared with 13.7% with semaglutide. (American College of Cardiology)

Is Ozempic the same as semaglutide?

Ozempic contains semaglutide. Semaglutide is also the active medication in Wegovy, although the FDA-approved indications and dosing differ.

Is Mounjaro the same as tirzepatide?

Mounjaro contains tirzepatide and is approved for type 2 diabetes. Zepbound also contains tirzepatide and is FDA approved for chronic weight management in qualifying patients. (U.S. Food and Drug Administration)

Are semaglutide and tirzepatide GLP-1 medications?

Semaglutide is a GLP-1 receptor agonist. Tirzepatide activates both GIP and GLP-1 receptors, so technically it is a dual GIP/GLP-1 receptor agonist.

Which GLP-1 medication is best during menopause?

There is no single medication that is best for every menopausal woman. The appropriate choice depends on medical history, cardiovascular and metabolic risk, amount of weight loss needed, medication tolerance, body composition, cost and individual response.

Can semaglutide or tirzepatide help with menopause weight gain?

They can be effective for appropriately selected women with overweight or obesity, but they are not treatments for menopause itself. Weight management during menopause should also address nutrition, resistance exercise, sleep, cardiovascular risk and preservation of muscle mass.